Literature DB >> 17193926

Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease.

Spiridon Papapetropoulos1, Jarlath Ffrench-Mullen, Donald McCorquodale, Yujing Qin, John Pablo, Deborah C Mash.   

Abstract

Combining large-scale gene expression approaches and bioinformatics may provide insights into the molecular variability of biological processes underlying neurodegeneration. To identify novel candidate genes and mechanisms, we conducted a multiregional gene expression analysis in postmortem brain. Gene arrays were performed utilizing Affymetrix HG U133 Plus 2.0 gene chips. Brain specimens from 21 different brain regions were taken from Parkinson's disease (PD) (n = 22) and normal aged (n = 23) brain donors. The rationale for conducting a multiregional survey of gene expression changes was based on the assumption that if a gene is changed in more than one brain region, it may be a higher probability candidate gene compared to genes that are changed in a single region. Although no gene was significantly changed in all of the 21 brain regions surveyed, we identified 11 candidate genes whose pattern of expression was regulated in at least 18 out of 21 regions. The expression of a gene encoding the mitochondria ribosomal protein S6 (MRPS6) had the highest combined mean fold change and topped the list of regulated genes. The analysis revealed other genes related to apoptosis, cell signaling, and cell cycle that may be of importance to disease pathophysiology. High throughput gene expression is an emerging technology for molecular target discovery in neurological and psychiatric disorders. The top gene reported here is the nuclear encoded MRPS6, a building block of the human mitoribosome of the oxidative phosphorylation system (OXPHOS). Impairments in mitochondrial OXPHOS have been linked to the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17193926      PMCID: PMC6032441          DOI: 10.3727/000000006783991827

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  50 in total

1.  Metaplasticity of the late-phase of long-term potentiation: a critical role for protein kinase A in synaptic tagging.

Authors:  Jennie Z Young; Carolina Isiegas; Ted Abel; Peter V Nguyen
Journal:  Eur J Neurosci       Date:  2006-04       Impact factor: 3.386

2.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Authors:  Michael A Hauser; Yi-Ju Li; Hong Xu; Maher A Noureddine; Yujun S Shao; Steven R Gullans; Clemens R Scherzer; Roderick V Jensen; Adam C McLaurin; Jason R Gibson; Burton L Scott; Rita M Jewett; Judith E Stenger; Donald E Schmechel; Christine M Hulette; Jeffery M Vance
Journal:  Arch Neurol       Date:  2005-06

Review 3.  Nuclear genes and mitochondrial translation: a new class of genetic disease.

Authors:  Howard T Jacobs; Douglass M Turnbull
Journal:  Trends Genet       Date:  2005-06       Impact factor: 11.639

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.

Authors:  A C Vernon; S Palmer; K P Datla; V Zbarsky; M J Croucher; D T Dexter
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

Review 7.  Molecular pathogenesis of Parkinson's disease.

Authors:  Sonia Gandhi; Nicholas W Wood
Journal:  Hum Mol Genet       Date:  2005-08-26       Impact factor: 6.150

Review 8.  Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family.

Authors:  Bryan Mackenzie; Jeffrey D Erickson
Journal:  Pflugers Arch       Date:  2003-07-04       Impact factor: 3.657

Review 9.  Mitochondrial ribosomal proteins: candidate genes for mitochondrial disease.

Authors:  James E Sylvester; Nathan Fischel-Ghodsian; Edward B Mougey; Thomas W O'Brien
Journal:  Genet Med       Date:  2004 Mar-Apr       Impact factor: 8.822

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  35 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  Translational defects in a mutant deficient in YajL, the bacterial homolog of the parkinsonism-associated protein DJ-1.

Authors:  Fatoum Kthiri; Valérie Gautier; Hai-Tuong Le; Marie-Françoise Prère; Olivier Fayet; Abderrahim Malki; Ahmed Landoulsi; Gilbert Richarme
Journal:  J Bacteriol       Date:  2010-10-01       Impact factor: 3.490

3.  DEGAS: de novo discovery of dysregulated pathways in human diseases.

Authors:  Igor Ulitsky; Akshay Krishnamurthy; Richard M Karp; Ron Shamir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

Review 4.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

Review 5.  Mitochondrial cross-compartmental signalling to maintain proteostasis and longevity.

Authors:  Marte Molenaars; Eileen G Daniels; Amber Meurs; Georges E Janssens; Riekelt H Houtkooper
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-05-04       Impact factor: 6.237

6.  Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration.

Authors:  Matthew L Neal; Sheila M Fleming; Kevin M Budge; Alexa M Boyle; Chunki Kim; Gelareh Alam; Eric E Beier; Long-Jun Wu; Jason R Richardson
Journal:  FASEB J       Date:  2019-12-04       Impact factor: 5.191

7.  SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Authors:  Lina A Shehadeh; Kristine Yu; Liyong Wang; Alexandra Guevara; Carlos Singer; Jeffery Vance; Spyridon Papapetropoulos
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

8.  Identification of Critical Genes and miRNAs Associated with the Development of Parkinson's Disease.

Authors:  Jia Li; Yajuan Sun; Jiajun Chen
Journal:  J Mol Neurosci       Date:  2018-08-06       Impact factor: 3.444

9.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.

Authors:  Changyoun Kim; Dong-Hwan Ho; Ji-Eun Suk; Sungyong You; Sarah Michael; Junghee Kang; Sung Joong Lee; Eliezer Masliah; Daehee Hwang; He-Jin Lee; Seung-Jae Lee
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.